Clinical Trial Details

Overview

Research Study Summary

A phase 3, randomized, double blind, parallel group, placebo-controlled, fixed dose study comparing the efficacy and safety of 2 doses (10 and 15mg) of Lu AA21004 in acute treatment of adults with major depressive disorder.

Purpose

The purpose of this study is to evaluate if 10 and 15mg of Lu AA21004 (the study drug) once a day compared with placebo will improve major depressive symptoms after eight weeks of treatment in patients with major depressive disorder.

Please contact Alexian Brothers for more information on participation.

To Learn more

CW ID: 176876
Date Last Changed: July 22, 2013

Clinical Trial Snapshot

Phase
3
Gender
Both Male and Female
Age
N/A
Overall Status
Recruiting
Facility Type
N/A

Contact

Alexian Brothers Hospital Network
1786 Moon Lake Boulevard, Suite 200
Hoffman Estates, IL 60169
Phone: 847-230-3599

View Map

Research Center Information:

Alexian Brothers Hospital Network

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.